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Regarding “Bovine thrombin injection for the
treatment of iatrogenic arterial pseudoaneurysms: Is
it too good to be true?”
We have read with interest numerous articles in the Journal of
Vascular Surgery since Liau et al1 first reported the use of bovine
thrombin injection for treatment of femoral artery pseudoaneu-
rysms. Subsequent authors have advocated percutaneous ultra-
sound-guided thrombin injection as the preferred treatment for
this condition, typically citing improved speed, effectiveness, and
patient tolerance versus ultrasound-guided compression. We have
performed thrombin injection with success rates similar to those in
the literature, but we have done so with caution and only after
careful patient selection.
While recognizing the potential for mechanical complications
with thrombin injection (eg, thromboembolism), most authors
forget or ignore other issues inherent to the material itself. Bovine
thrombin is approved by the Food and Drug Administration for
topical application, but its intravascular use is off-label. Biologic
compounds such as bovine thrombin are assayed for activity and
sterility, not purity, and bovine thrombin contains other bovine
plasma proteins such as factor V. Bovine thrombin is highly immu-
nogenic, and numerous reports document immune-mediated reac-
tions to its topical use, including fatal hemorrhagic complications.2,3
Dorion et al2 reviewed blood samples from 120 patients
exposed to topical bovine thrombin and found that 12 patients
(10%) demonstrated antibodies to bovine thrombin and other
coagulation factors. In 2 patients (1.7%) severe bleeding devel-
oped, requiring complex management. Repeated exposure to bo-
vine thrombin was associated with an eightfold increase in inci-
dence of antibody formation: 7 of 18 patients (39%) versus 5 of
102 patients (5%) (P .001). In a prospective study of 150 cardiac
surgery patients exposed to topical bovine thrombin, Ortel et al3
reported that 51% had elevated antibodies to human coagulation
proteins, most commonly factor V. Coagulopathy was common in
these patients, but clinically significant adverse events occurred
more frequently in patients who, because of previous exposure,
had elevated concentrations of multiple antibodies before surgery.
The unadjusted odds ratio of an adverse event in this setting was
calculated at 5.40. Intravascular use likely has similar potential for
sensitization, although this has not yet been reported in the
literature. Of interest, two published reports describe “allergic”-
type reactions after use of bovine thrombin for arterial pseudoan-
eurysm treatment, including anaphylaxis in one patient4 and gen-
eralized urticarial reaction in another patient.5
Considering these reports, it seems prudent to limit the use of
intravascular bovine thrombin to those cases that truly warrant it.
An alternative, human thrombin, may be less immunogenic and is
commercially available as a fibrin sealant. Two published reports
describe use of human thrombin to treat arterial pseudoaneurysms,
with results similar to those with bovine thrombin.6,7 We currently
maintain bovine thrombin in our armamentarium, but recognize
its potential for causing serious injury to our patients, especially
those who have had prior exposure to bovine thrombin, topical or
otherwise. We reserve the use of bovine thrombin for those pa-
tients in whom graded compression has failed or is not amenable.
In our opinion, any history of bovine thrombin exposure is a
contraindication to its further use. Absent other options, most
patients can tolerate limited surgical femoral exposure with direct
repair.
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